Harmony Biosciences (HRMY) announced that it has completed its acquisition of Zynerba Pharmaceuticals (ZYNE). As a result of the merger, Zynerba became a wholly owned subsidiary of Harmony. The common stock of Zynerba will no longer be listed for trading on the Nasdaq Capital Market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
- Harmony Biosciences’ pitolisant shows behavior improvement in PWS
- Harmony Biosciences reports receipt of Wakix paragraph IV certification notices
- Zynerba stockholders reminded to tender shares
- Mizuho ‘defending’ Harmony Biosciences after 10% pullback